SUBCUTANEOUS VS INTRAVENOUS ADMINISTRATION OF TRASTUZUMAB IN HER2+BREAST CANCER PATIENTS: A MACEDONIAN COST-MINIMIZATION ANALYSIS

被引：2
|
作者：
Nestorovska, A. [1 ]
Naumoska, Z. [1 ]
Grozdanova, A. [1 ]
Stoleski, D. [2 ]
Ivanovska, A. [2 ]
Risteski, M. [3 ]
Vasev, N. [3 ]
Ismaili, I. [3 ]
Stefanovski, P. [4 ]
Dimovski, A. [1 ]
Suturkova, L. [1 ]
Sterjev, Z. [5 ]
机构：
[1] ISPOR Republ Macedonia Reg Chapter, Skopje, Macedonia
[2] DOOEL, Roche Macedonia, Skopje, Macedonia
[3] Univ Clin Radiotherapy & Oncol, Skopje, Macedonia
[4] Clin Hosp, Bitola, Macedonia
[5] UKIM Skopje, Fac Pharm, Skopje, Macedonia
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1205
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN188
引用
收藏
页码：A463 / A463
页数：1
相关论文
共 50 条
  • [21] Cost minimization analysis of subcutaneous trastuzumab versus intravenous biosimilar trastuzumab: policy recommendations for breast cancer treatment in Malaysia
    Jin Ee Heng
    Sivaraj Raman
    Zhi Yen Wong
    Valerine Jen Nin Beh
    DARU Journal of Pharmaceutical Sciences, 2024, 32 : 67 - 76
  • [22] COST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAINCO ST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAIN
    Colomer, R.
    Ciruelos, E.
    De la Haba, J.
    Martin, M.
    De Salas-Cansado, M.
    Munoz-Molina, B.
    Albanell, J.
    VALUE IN HEALTH, 2016, 19 (07) : A740 - A740
  • [23] Pruritus related to trastuzumab and pertuzumab in HER2+breast cancer patients
    Gu, Stephanie
    Dusza, Stephen
    Quigley, Elizabeth
    Haliasos, Helen
    Markova, Alina
    Marchetti, Michael
    Moy, Andrea P.
    Dang, Chau
    Modi, Shanu
    Lake, Diana
    Noor, Sarah
    Lacouture, Mario E.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (02) : 271 - 280
  • [24] A Review and Meta-analysis on Trastuzumab Resistance in Patients with HER2+Breast Cancer
    Holzbach, Alexandre
    Cima, Bernardo Perin
    Staffen, Mari Dalva
    Lindenau, Juliana Dal-Ri
    Muniz, Yara Costa Netto
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2023, 23 (11) : 1222 - 1236
  • [25] Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+Breast Cancer (ADEPT trial)
    Waks, Adrienne G.
    Chen, Emily L.
    Graham, Noah
    Frey, Anna Mae
    Almeida, Kenneth
    Attaya, Victoria
    Ryding, Cari
    Abbass, Ibrahim
    Fung, Anita
    Sussell, Jesse
    Cortazar, Patricia
    Harvey, Caroline
    Leth, Denise
    Faggen, Meredith
    Sinclair, Natalie
    Walsh, Jeanna
    Tung, Nadine
    Sinclair, Sarah
    Lo, Steve
    Yardley, Denise
    Valero, Vicente
    Meisel, Jane
    Ballinger, Tarah J.
    Adams, Sylvia
    Carey, Lisa A.
    Rauch, Julia K.
    Abramson, Vandana G.
    Williams, Nicole O.
    Chen, Wendy Y.
    Leone, Jose P.
    Schumer, Susan T.
    Tayob, Nabihah
    Tolaney, Sara M.
    JCO ONCOLOGY PRACTICE, 2025, 21 (03)
  • [26] PREFERENCE OF MACEDONIAN NHL PATIENTS FOR SUBCUTANEOUS VS INTRAVENOUS ADMINISTRATION OF RITUXIMAB
    Stojanovikj, A.
    Cvetanovska, L.
    Chevreska, L.
    Adzija, D.
    Milchevska, B.
    Smokovski, A.
    LEUKEMIA RESEARCH, 2017, 61 : S32 - S32
  • [27] Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients.
    Elsamany, Shereef
    Elsisi, Gihan Hamdy
    Hassanin, Fayza
    Jafal, Mohamed
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 511 - 518
  • [28] Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+breast cancer.
    Garrison, L. P., Jr.
    Perez, E. A.
    Dueck, A.
    Lalla, D.
    Paton, V.
    Lubeck, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 306S - 306S
  • [29] Dual HER2 blockage with lapatinib and trastuzumab for Japanese patients with HER2+breast cancer
    Iwata, H.
    Yamamoto, N.
    Masuda, N.
    Bando, H.
    Kuroi, K.
    Ohno, S.
    Kasai, H.
    Morita, S.
    Sakurai, T.
    Toi, M.
    BREAST, 2015, 24 : S95 - S95
  • [30] Safety of trastuzumab in women with HER2+breast cancer.
    Nowsheen, Somaira
    Aziz, Khaled
    Park, Jae Yoon
    Villarraga, Hector R.
    Herrmann, Joerg
    Ruddy, Kathryn Jean
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345